Xigen Inflammation Ltd.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Xigen Inflammation Ltd..The latest application filed is for "use for jnk inhibitor molecules for treatment of various diseases".

Company Profile

10.20.25

Xigen Inflammation Ltd. - Limassol CY

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Use For JNK Inhibitor Molecules For Treatment Of Various Diseases App 20220280591 - COMBETTE; Jean-Marc ; et al.	2022-09-08
Use for JNK inhibitor molecules for treatment of various diseases Grant 11,331,364 - Combette , et al. May 17, 2	2022-05-17
Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases Grant 10,967,038 - Combette , et al. April 6, 2	2021-04-06
JNK Inhibitor Molecules For Treatment Of Various Diseases App 20200206301 - COMBETTE; Jean-Marc ; et al.	2020-07-02
Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases Grant 10,624,948 - Combette , et al.	2020-04-21
Use For JNK Inhibitor Molecules for Treatment of Various Diseases App 20200093883 - Combette; Jean-Marc ; et al.	2020-03-26
JNK inhibitor molecules for treatment of various diseases Grant 10,596,223 - Combette , et al.	2020-03-24
Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway App 20200062805 - Bonny; Christophe	2020-02-27
Novel Transporter Constructs And Transporter Cargo Conjugate Molecules App 20190337988 - Bonny; Christophe	2019-11-07
Use Of Cell-permeable Peptide Inhibitors Of The Jnk Signal Transduction Pathway For The Treatment Of Chronic Or Non-chronic Inflammatory Eye Diseases App 20190060392 - Combette; Jean-Marc ; et al.	2019-02-28
Efficient transport into white blood cells Grant 10,023,615 - Bonny July 17, 2	2018-07-17
New Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Mild Cognitive Impairment App 20180170983 - Combette; Jean-Marc ; et al.	2018-06-21
Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway App 20170320917 - Bonny; Christophe	2017-11-09
Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Various Diseases App 20170290877 - Combette; Jean-Marc ; et al.	2017-10-12
Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Various Diseases App 20170137481 - Combette; Jean-Marc ; et al.	2017-05-18
Use for JNK Inhibitor Molecules for Treatment of Various Diseases App 20170128516 - Combette; Jean-Marc ; et al.	2017-05-11
JNK inhibitor molecules Grant 9,624,267 - Bonny April 18, 2	2017-04-18
Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases Grant 9,610,330 - Bonny April 4, 2	2017-04-04
Novel JNK inhibitor Molecules for Treatment of Various Diseases App 20170056466 - COMBETTE; Jean-Marc ; et al.	2017-03-02
Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway App 20160264630 - Bonny; Christophe	2016-09-15
New Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Various Diseases App 20160199444 - Combette; Jean-Marc ; et al.	2016-07-14
New Use for JNK Inhibitor Molecules for Treatment of Various Diseases App 20160115200 - Combette; Jean-Marc ; et al.	2016-04-28
Use Of Cell-permeable Peptide Inhibitors Of The Jnk Signal Transduction Pathway For The Treatment Of Chronic Or Non-chronic Inflammatory Eye Diseases App 20160089413 - COMBETTE; JEAN-MARC ; et al.	2016-03-31
Cell-permeable peptide inhibitors of the JNK signal transduction pathway Grant 9,290,538 - Bonny March 22, 2	2016-03-22
Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases Grant 9,180,159 - Bonny November 10, 2	2015-11-10
Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases Grant 9,150,618 - Combette , et al. October 6, 2	2015-10-06
Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Various Diseases App 20150246099 - Bonny; Christophe	2015-09-03
Novel JNK Inhibitor Molecules for Treatment of Various Diseases App 20150133393 - Combette; Jean-Marc ; et al.	2015-05-14
Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases Grant 9,006,185 - Bonny April 14, 2	2015-04-14
JNK inhibitor molecules Grant 8,981,052 - Bonny March 17, 2	2015-03-17
Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Dry Eye Syndrome App 20140309400 - Combette; Jean-Marc ; et al.	2014-10-16
Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway App 20140200187 - Bonny; Christophe	2014-07-17
Cell-permeable peptide inhibitors of the JNK signal transduction pathway Grant 8,748,395 - Bonny June 10, 2	2014-06-10

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.